Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Malignant Lymphoma

  Free Subscription


08.07.2019

1 Blood
1 BMC Cancer
1 Br J Dermatol
3 Br J Haematol
2 Cancer Res
1 Eur J Haematol
1 Haematologica
1 Int J Radiat Oncol Biol Phys
2 Lancet Oncol
4 Leuk Lymphoma


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Blood

  1. SAUTER CS, Senechal B, Riviere I, Ni A, et al
    CD19 CAR T Cells Following Autologous Transplantation in Poor Risk Relapsed and Refractory B cell non-Hodgkin Lymphoma.
    Blood. 2019 Jul 1. pii: blood.2018883421. doi: 10.1182/blood.2018883421.
    PubMed     Text format     Abstract available


    BMC Cancer

  2. HICKMANN AK, Frick M, Hadaschik D, Battke F, et al
    Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.
    BMC Cancer. 2019;19:192.
    PubMed     Text format     Abstract available


    Br J Dermatol

  3. HAO-ZE S, Liu YX, Jiang YQ, Chen SL, et al
    Clinical characteristics of primary cutaneous lymphoma: two centers analysis in China.
    Br J Dermatol. 2019 Jul 1. doi: 10.1111/bjd.18266.
    PubMed     Text format     Abstract available


    Br J Haematol

  4. MATSUE K, Abe Y, Narita K, Kobayashi H, et al
    Diagnosis of intravascular large B-cell lymphoma: novel insights into clinicopathological features from 42 patients at a single institution over 20 years.
    Br J Haematol. 2019 Jul 3. doi: 10.1111/bjh.16081.
    PubMed     Text format     Abstract available

  5. YORDANOVA K, Stilgenbauer S, Bohle RM, Lesan V, et al
    Spontaneous regression of a plasmablastic lymphoma with MYC rearrangement.
    Br J Haematol. 2019 Jul 1. doi: 10.1111/bjh.16082.
    PubMed     Text format    

  6. PRUSILA REI, Sorigue M, Jauhiainen J, Mercadal S, et al
    Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era.
    Br J Haematol. 2019 Jul 3. doi: 10.1111/bjh.16090.
    PubMed     Text format     Abstract available


    Cancer Res

  7. GAMBI G, Di Simone E, Basso V, Ricci L, et al
    The Transcriptional Regulator Sin3A Contributes to the Oncogenic Potential of STAT3.
    Cancer Res. 2019;79:3076-3087.
    PubMed     Text format     Abstract available

  8. ROSS J, Rashkovan M, Fraszczak J, Joly Beauparlant C, et al
    Deletion of the Miz-1 POZ domain increases efficacy of cytarabine treatment in T- and B-ALL/lymphoma mouse models.
    Cancer Res. 2019 Jul 4. pii: 0008-5472.CAN-18-3038.
    PubMed     Text format     Abstract available


    Eur J Haematol

  9. DADA R
    Diagnosis and management of follicular lymphoma: A comprehensive review.
    Eur J Haematol. 2019 Jun 10. doi: 10.1111/ejh.13271.
    PubMed     Text format     Abstract available


    Haematologica

  10. FALGAS A, Pallares V, Unzueta U, Cespedes MV, et al
    A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models.
    Haematologica. 2019 Jun 27. pii: haematol.2018.211490.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  11. CAMPBELL BA, Plastaras JP, Savage KJ
    Keeping our finger on the pulse: reaffirming the role of radiotherapy in the curative management of early stage follicular lymphoma.
    Int J Radiat Oncol Biol Phys. 2019 Jun 26. pii: S0360-3016(19)33393.
    PubMed     Text format    


    Lancet Oncol

  12. KIM DD, Budhram A, Haji FA, Leung A, et al
    Leptomeningeal metastasis of classical Hodgkin lymphoma in a patient with malignant posterior reversible encephalopathy syndrome.
    Lancet Oncol. 2019;20:e397.
    PubMed     Text format    

  13. BAGOT M, Porcu P, Marie-Cardine A, Battistella M, et al
    IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.
    Lancet Oncol. 2019 Jun 25. pii: S1470-2045(19)30320.
    PubMed     Text format     Abstract available


    Leuk Lymphoma

  14. GOLDSTEIN JS, Switchenko JM, Behera M, Flowers CR, et al
    Insurance status impacts overall survival in Burkitt lymphoma.
    Leuk Lymphoma. 2019 Jul 5:1-10. doi: 10.1080/10428194.2019.1623884.
    PubMed     Text format     Abstract available

  15. CANDELARIA M, Gonzalez DE, Delamain MT, Bar DO, et al
    Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study.
    Leuk Lymphoma. 2019 Jul 4:1-11. doi: 10.1080/10428194.2019.1633632.
    PubMed     Text format     Abstract available

  16. OON ML, Hoppe MM, Fan S, Phyu T, et al
    The contribution of MYC and PLK1 expression to proliferative capacity in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2019 Jul 1:1-11. doi: 10.1080/10428194.2019.1633629.
    PubMed     Text format     Abstract available

  17. ANNIBALI O, Hohaus S, Marchesi F, Cantonetti M, et al
    The neutrophil/lymphocyte ratio >/=3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network 'Rete Ematologica del Lazio per i Linfomi' (RELLI).
    Leuk Lymphoma. 2019 Jul 1:1-9. doi: 10.1080/10428194.2019.1633628.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: